Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...
Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to ...
Company’s Shares Will Continue to Trade Under Ticker CERO on the OTC MarketsSOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- ...
86% ORR, 63% CR rate, 53% PFS at 12 months in patients who received vispa-cel with an optimized profile (N=35) Vispa-cel is generally well-tolerated, allowing for administration in the outpatient ...
DREAM IMPACT TRUST (TSX: MPCT.UN) ("Dream Impact", "we", "our" or the "Trust") today reported its financial results for the three and nine months ended September 30, 2025 ("third quarter").
clinical updates of the ALLOHA Phase 1 heme trial, presentation of data, dosing of patients, filing of an new IND applications and initiation of Phase 1 development, and clinical trial design and ...
Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first clinical data from dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback